Molecular mechanisms underlying ErbB2/HER2 action in breast cancer (Q34130548)

31 July 2017

title

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer (English)

1 reference

31 July 2017

1 reference

Harari D

1

1 reference

31 July 2017

Yarden Y

series ordinal

2

1 reference

31 July 2017

publication date

1 December 2000

1 reference

31 July 2017

language of work or name

0 references

1 reference

31 July 2017

volume

19

1 reference

31 July 2017

issue

53

1 reference

31 July 2017

page(s)

6102-6114

1 reference

publication type of scholarly work

31 July 2017

review article

1 reference

Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The structural basis for the specificity of epidermal growth factor and heregulin binding

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

‘Revertant’ DCIS in human axillary breast carcinoma metastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Aberrations of the G1- and G1/S-regulating genes in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Cyclin D1 protein expression and function in human breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Receptors for epidermal growth factor and steroid hormones in human breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Ligands for ErbB-family receptors encoded by a neuregulin-like gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Expression of transforming growth factor alpha (TGF alpha) in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection ofcyclin D1 in breast andcyclin E in ovarian tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Differential Signaling by the Epidermal Growth Factor-like Growth Factors Neuregulin-1 and Neuregulin-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

WAF1, a potential mediator of p53 tumor suppression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Mice lacking cyclin D1 are small and show defects in eye and mammary gland development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

A role for E2F1 in Ras activation of p21(WAF1/CIP1) transcription

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Transcriptional Regulation of the p21(WAF1/CIP1)Gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Rescue of Cyclin D1 Deficiency by Knockin Cyclin E

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Rac and Cdc42 are potent stimulators of E2F-dependent transcription capable of promoting retinoblastoma susceptibility gene product hyperphosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Expression of epidermal growth factor-related proteins in the aged adult mouse mammary gland and their relationship to tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Mechanism of action of taxol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Signaling--2000 and beyond

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The biology of erbB-2/neu/HER-2 and its role in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

High-resolution solution structure of the EGF-like domain of heregulin-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Binding specificities and affinities of egf domains for ErbB receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Ras induces p21Cip1/Waf1 cyclin kinase inhibitor transcriptionally through Sp1-binding sites

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

New functional activities for the p21 family of CDK inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Requirement for neuregulin receptor erbB2 in neural and cardiac development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Expression of the ERBB3 gene product in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Heregulin regulation of Akt/protein kinase B in breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The Neuregulin Precursor proARIA Is Processed to ARIA after Expression on the Cell Surface by a Protein Kinase C-Enhanced Mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Membrane-anchored growth factors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

17 beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Multiple essential functions of neuregulin in development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Selective regulation of steroid receptor expression in MCF-7 breast cancer cells by a novel member of the heregulin family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Expression of c-erbB3 protein in primary breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Epidermal growth factor-related peptides in the pathogenesis of human breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Differential immunohistochemical detection of transforming growth factor α, amphiregulin and CRIPTO in human normal and malignant breast tissues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

There must be 50 ways to rule the signal: the case of the Drosophila EGF receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Activation of ErbB4 by the Bifunctional Epidermal Growth Factor Family Hormone Epiregulin Is Regulated by ErbB2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The cellular response to neuregulins is governed by complex interactions of the erbB receptor family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Correlation of erbB-2 gene amplification with low levels of estrogen and/or progesterone receptors in primary breast cancer: do erbB-2 products delineate hormone-independent tumors?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Growth factor signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Secreted Spitz triggers the DER signaling pathway and is a limiting component in embryonic ventral ectoderm determination.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

CDK inhibitors: positive and negative regulators of G1-phase progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Strain-dependent epithelial defects in mice lacking the EGF receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Cyclin D1 provides a link between development and oncogenesis in the retina and breast

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Biochemical characterization of mutant EGF receptors expressed in the hemopoietic cell line BaF/3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The retinoblastoma protein and cell cycle control

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

A point mutation in the neu oncogene mimics ligand induction of receptor aggregation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The oncogene heregulin induces apoptosis in breast epithelial cells and tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Structural and functional aspects of the multiplicity of Neu differentiation factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Overexpression of cyclin D1 in epithelial ovarian cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

p21 is a universal inhibitor of cyclin kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

p21-containing cyclin kinases exist in both active and inactive states

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

The EGF receptor as central transducer of heterologous signalling systems

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1203973

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1203973

1 reference

Dimensions publication ID

31 July 2017

1039053742

0 references

1 reference